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Extending the FSH window for multifollicular development
by administering FSH from the midfollicular phase onward
constitutes a novel mild protocol for ovarian stimulation for
in vitro fertilization (IVF) based on the physiology of single
dominant follicle selection in normo-ovulatory women. We
compared outcomes from this protocol with two other stim-
ulation protocols. One hundred and forty-two normo-ovula-
tory patients with an indication for IVF (or IVF/ICSI) were
randomized to a GnRH agonist long protocol (group A; n 45)
or one of two GnRH antagonist protocols commencing recom-
binant FSH on cycle d 2 (group B; n  48) or cycle d 5 (group
C; n 49). A fixed dose (150 IU/d) of rFSH was used for ovarian
stimulation, and GnRH antagonist cotreatment was initiated
on the day when the leading follicle reached 14 mm diameter.
Group C showed a shorter duration of stimulation (median
duration, 11, 9, and 8 d for groups A, B, and C, respectively; P <
0.001), reflected in a significantly lower total dose of rFSH
used (median amount of rFSH, 1650, 1350, and 1200 IU for
groups A, B, and C, respectively; P < 0.001). In group C more
cycles were cancelled during the stimulation phase due to
insufficient response, resulting in a lower percentage of oo-
cyte retrievals (84%, 73%, and 63% for groups A, B, and C; P 
0.02). However, women in group C obtained better quality
embryos (percentage of embryo score of 1 for best embryo,
29%, 37%, and 61% for groups A, B, and C, respectively; P 
0.008), resulting in more transfers per oocyte retrieval (68%,
71%, and 90% for groups A, B, and C, respectively; P  0.04).
After profound ovarian stimulation (groups A and B) only 7%
of the patients who retrieved four oocytes or less conceived,
whereas after mild stimulation (group C) 67% of these patients
conceived (P < 0.01). Overall, no differences were found
among the three groups comparing pregnancy rate per
started IVF cycle.
In conclusion, application of the described mild ovarian
stimulation protocol resulted in pregnancy rates per started
IVF cycle similar to those observed after profound stimulation
with GnRH agonist cotreatment despite shorter stimulation
and a 27% reduction in exogenous FSH. A higher cancellation
rate before oocyte retrieval was compensated by improved
embryo quality concomitant with a higher chance of under-
going embryo transfer. A relatively low number of oocytes
retrieved after mild ovarian stimulation distinctly differs
from the pathological reduction in the number of oocytes re-
trieved after profound ovarian stimulation (poor response)
associated with poor IVF outcome. The relatively small num-
ber of oocytes obtained after mild ovarian stimulation may
represent the best of the cohort in a given cycle. (J Clin En-
docrinol Metab 88: 166–173, 2003)
CONVENTIONAL OVARIAN STIMULATION proto-cols aim to stimulate the growth of many follicles to
obtain multiple oocytes for in vitro fertilization (IVF) and thus
multiple embryos, allowing selection for transfer (1). Cur-
rently applied standard IVF protocols take many weeks, are
complex and expensive, and are not without risk. Problems
related to ovarian stimulation include emotional stress, ab-
dominal discomfort, short-term complications such as ovar-
ian hyperstimulation syndrome and multiple gestation, and
uncertainties regarding long-term health consequences (2).
Many of the problems associated with current IVF stimula-
tion regimens relate to the unphysiological approach to ovar-
ian (hyper)stimulation (3). Preceding the administration of
high doses of gonadotropins, pituitary down-regulation is
normally achieved by prolonged administration of GnRH
agonists (the so-called long protocol). To date, IVF practice
has focused on optimizing success in terms of pregnancy rate
per started IVF cycle. Profound ovarian stimulation is there-
fore applied, despite the above-mentioned side-effects, risks,
and costs. If the balance between the risks and benefits of IVF
treatment is to improve, a paradigm shift is required in the
approach to treatment and in the way success from IVF is
defined. Increasing knowledge regarding the physiology of
ovarian follicle development and dominant follicle selection
(4) together with the clinical availability of new compounds,
such as GnRH antagonists (5), have presented the opportu-
nity to develop novel, milder approaches for ovarian stim-
ulation for IVF (6).
During the luteo-follicular transition in the normal men-
strual cycle, FSH concentrations rise and surpass the thresh-
Abbreviations: E2, Estradiol; ET, embryo transfer; hCG, human cho-
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old, stimulating a cohort of small antral follicles to grow (4).
Around the midfollicular phase, the most mature follicle
gains dominance over other cohort follicles (7). This domi-
nant follicle continues its growth despite decremental FSH
concentrations (8), whereas the remaining follicles from the
recruited cohort enter atresia due to insufficient stimulation
by FSH. This decreasing FSH level and subsequent closure of
the FSH gate (9) or window (10) appears essential for single
dominant follicle selection.
Multifollicular growth is established in current IVF pro-
tocols by generating FSH serum concentrations far above the
threshold from the early follicular phase for an extended
period. However, single dominant follicle selection may be
disrupted by the administration of low doses of exogenous
FSH during the mid to late follicular phase, effectively pre-
venting the physiological decrease in FSH concentrations (11,
12). The clinical introduction of GnRH antagonists in IVF
(13–17) allows ovarian stimulation to be commenced in the
undisturbed menstrual cycle. Extending the FSH window by
administering low dose exogenous FSH from the mid to late
follicular phase may indeed be effective in IVF (18), resulting
in a shorter and more patient-friendly treatment cycle. How-
ever, it remains unclear whether the reduced number of
oocytes obtained after mild stimulation may impair outcome
(2). To address these issues, we carried out a prospective
randomized study comparing stimulation characteristics
and IVF outcomes of the standard long GnRH agonist pro-
tocol for ovarian stimulation with two GnRH antagonist
protocols commencing FSH in the early or midfollicular
phase.
Subjects and Methods
Subjects and study design
This study was approved by the local ethics review committee. Writ-
ten informed consent was obtained from each participant. Between
November 1999 and May 2001, 169 patients with an indication for IVF
with or without intracytoplasmic sperm injection (ICSI) were recruited.
After assignment to IVF or IVF/ICSI (those patients with a total motile
sperm count 1.0  106), randomization was performed to 1 of the 3
treatment groups using a computer-generated randomization schedule
assigned via numbered sealed envelopes.
Inclusion criteria were 1) age between 20–38 yr; 2) body mass index
(body weight divided by the square of body height) between 19–29
kg/m2; 3) history of regular menstrual cycles, ranging from 25–35 d;
4) no relevant systemic disease, severe endometriosis, or uterine and
ovarian abnormalities; 5) no more than three previous IVF cycles; and
6) no previous IVF cycle with a poor response or ovarian hyperstimu-
lation syndrome.
Group A was treated with the GnRH agonist triptoreline (Decapeptyl,
Ferring Pharmaceuticals Ltd., Hoofddorp, The Netherlands; 1 mg/d, sc)
starting 1 wk before the expected menses (usually cycle d 21). After
down-regulation was achieved [serum estradiol (E2),150 pmol/liter],
ovarian stimulation was commenced with a fixed daily dose of 150 IU
recombinant FSH (rFSH), sc (Gonal-F, Serono Benelux BV, The Hague,
The Netherlands). Groups B and C were treated with the GnRH antag-
onist cetrorelix (Cetrotide, ASTA Medica, Amsterdam, The Netherlands;
0.25 mg/d, sc) commencing when the largest follicle had reached a
diameter of 14 mm, as previously described (18). rFSH was initiated on
cycle d 2 (group B) or 5 (group C). Triptoreline and cetrorelix were
continued up to and including the day of human chorionic gonadotropin
(hCG) administration. When the leading follicle had reached a diameter
of 18 mm or more and at least three follicles had reached a diameter of
15 mm or more, rFSH was stopped, and a single sc bolus of 10,000 IU
hCG (Pregnyl, NV Organon, Oss, The Netherlands) was administered
35 h before the planned time of oocyte retrieval. All follicles 12 mm or
larger were aspirated. Subsequently, IVF with or without ICSI was
performed, and a maximum of two embryos were transferred 3–5 d
thereafter, as described previously (19). All embryos were scored on the
day of embryo transfer (ET) between 0800–1000 h. Luteal support in the
form of intravaginal progesterone (P; Progestan, Organon; 200 mg, three
times daily) was given from the day of oocyte retrieval until a urine
pregnancy test was performed 17 d later. A schematic description of the
applied treatment regimens is given in Fig. 1.
Assessments
Baseline blood sampling and transvaginal sonography (TVS) were
performed on cycle d 2 or 3 of the pretreatment cycle in group A and
on cycle d 2 of the treatment cycle in groups B and C. Monitoring of
response during the treatment cycle consisted of TVS and blood sam-
FIG. 1. Schematic representation of
the three studied stimulation regimens:
a GnRH agonist long protocol and two
late follicular phase GnRH antagonist
protocols with start of a fixed dose of
rFSH on cycle d 2 or cycle d 5.
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pling (cycle d 2, 5, and 8; day of hCG administration; day of oocyte
retrieval, and 7 d thereafter) for hormonal analysis (E2, FSH, LH, and P).
Additional TVS monitoring was performed as clinically indicated.
Embryo scoring was carried out on the day of ET (3, 4, or 5 d after
oocyte retrieval) blinded to the stimulation protocol. Scoring was based
on developmental stage and morphology, using previously described
criteria (19, 20). Scoring criteria for d 3 embryos included cell number,
regularity of blastomeres, fragmentation, and morphological aspects
such as granulation. Criteria for d 4 embryos included the degree of
embryo compaction and the presence of separated cells or fragments.
Day 5 embryos were scored using criteria including embryonic stage,
cavitation, inner cell mass, and cell morphology. When no fragmentation
was evident and the developmental stage was appropriate for their age,
embryos were described as high grade and given an embryo score of 1.
Embryos showing developmental delay and more than 50% fragmen-
tation were described as low grade and scored as 4. Embryos of better
and worse intermediate quality were given embryo scores of 2 and 3,
respectively.
In the case of a positive urine pregnancy test (biochemical pregnancy),
an ultrasound scan was carried out 5–6 wk after oocyte retrieval to
determine the viability of the pregnancy. A second ultrasound was
performed at 12 wk gestation to confirm an ongoing pregnancy (positive
heart beat).
Hormone assays
Blood samples were centrifuged within 2 h after withdrawal and
stored at –20 C until assayed. Serum FSH, LH, and P levels were assessed
by chemiluminescent immunoassay (Immulite, Diagnostic Products,
Los Angeles, CA). Serum E2 levels were measured using RIA kits (Di-
agnostic Products), as described previously (21). Dimeric inhibin B levels
were determined using an immunoenzymometric assay (Serotec, Ox-
ford, UK), as described previously (22). Intra- and interassay coefficients
of variation were less than 5% and 7% for FSH, less than 5% and 6% for
LH, less than 10% and 10% for P, less than 5% and 7% for E2, and less
than 8% and 14% for inhibin B, respectively.
Data analysis
The power calculation for this study was based on E2 levels on the
day of hCG administration, because E2 provides a measure of ovarian
response and correlates with the number of follicles and oocytes. Pre-
vious studies from our own group have indicated that late follicular
phase mean E2 levels between 2800 and 4500 nmol/liter do not represent
clinically important differences in ovarian response (18, 23), whereas
concentrations below this range are associated with poor outcome. To
detect whether a given stimulation protocol was associated with re-
duced ovarian response compared with the other stimulation protocols,
represented by E2 levels below 2800 nmol/liter (with 90% power and
P  0.05), at least 120 patients (40/group) were needed. Eligibility for
analysis after inclusion or protocol violations was decided by a third
party, blinded for the randomization protocol.
Results are presented as the median and range unless otherwise
indicated. Comparisons of outcome measures among the three random-
ized groups were performed using the Kruskal-Wallis H test for con-
tinuous data and the 2 test for binary variables. Two-group compari-
sons were made using the Mann-Whitney U test. Pearson’s correlation
coefficients were calculated. P values are two-sided, and P  0.05 was
considered the limit of statistical significance. Data were analyzed
using the commercially available software package SPSS (SPSS, Inc.,
Chicago, IL).
Results
Subjects and baseline characteristics
Of the 169 patients randomized, 13 patients failed to start
IVF treatment within the study period. Fourteen patients
were excluded from analysis because of inclusion (n 4) and
protocol (n  10) violations (4 of whom conceived). The
remaining 142 patients (45, 48, and 49 patients for groups A,
B, and C, respectively) were included in the data analysis.
With regard to the distribution of age, body mass index,
TABLE 1. Patient characteristics and clinical IVF outcome (median and range) of a randomized comparison between a GnRH agonist
protocol and two GnRH antagonist protocols commencing rFSH on cycle d 2 or cycle d 5, respectively
GnRH agonist
long protocol
(n  45)
GnRH antagonist
rFSH d 2 start
(n  48)
GnRH antagonist
rFSH d 5 start
(n  49)
Pa
Included patients (n  142)
Age (yr) 33 (25–39) 33 (26–38) 33 (24–39) 0.36
Body mass index (kg/m2) 23.0 (19.6–28.1) 24.2 (19.7–28.4) 22.9 (19.7–29.0) 0.08
FSHday 2/3 (IU/liter) 5.5 (1.0–10.8) 6.3 (2.0–16.0) 6.3 (2.1–29.4) 0.38
Inhibin Bday 2/3 (ng/liter) 124 (21–292) 104 (11–260) 104 (18–727) 0.12
Patients undergoing oocyte retrieval (n  104)
n (% per started cycle) 38 (84%) 35 (73%) 31 (63%) 0.02
Cycle day start cetrorelixb 8 (5–12) 10 (8–14) 0.007
Day hCG
FSH (IU/liter) 6.5 (2.8–11.3) 6.6 (4.6–9.3) 6.8 (3.5–12.7) 0.66
LH (IU/liter) 1.0 (0.1–2.6) 0.7 (0.1–5.3) 1.5 (0.1–5.8) 0.09
E2 (nmol/liter) 3,407 (850–10,347) 2,555 (653–8,045) 3,193 (901–14,992) 0.23
P (nmol/liter) 2.5 (0.6–6.1) 2.8 (0.8–6.1) 3.1 (0.7–7.3) 0.38
No. of follicles (10 mm)day hCG 10 (4–21) 8 (3–27) 8 (3–22) 0.07
No. of follicles (15 mm)day hCG 5 (3–17) 5 (3–11) 4 (3–10) 0.20
No. of oocytes retrieved 9 (1–25) 8 (2–31) 7 (1–27) 0.57
No. of embryos 4 (0–16) 4 (0–13) 3 (0–19) 0.99
Fertilization rate per subject (%) 50 (0–100) 54 (0–100) 68 (0–100) 0.12
No. of pregnancies (%)c 10 (22%) 10 (20%) 10 (20%) 0.96
No. of ongoing pregnancies (%)d 8 (18%) 8 (17%) 8 (16%) 0.98
No. of twin pregnancies (%)e 3 (38%) 2 (25%) 3 (38%) 0.83
a Kruskal-Wallis H test for continuous data; 2 test for binary variables.
b Largest follicle 14 mm.
c Defined as a positive urine hCG test (percentage per started cycle).
d Defined as positive heart beat on ultrasound at 12 wk gestation (percentage per started cycle).
e Percentage of ongoing pregnancies.
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and baseline serum concentrations for FSH and inhibin B, no
significant differences were found among the three groups
(Table 1). There was no difference among the three groups
in cycle length [median cycle lengths in groups A, B, and C,
28 d (range, 25–35), 28 d (range, 25–33), and 28 d (range,
25–33), respectively; P  0.69] or the duration of infertility
[median durations in groups A, B, and C, 3.5 yr (range,
0.6–12.0), 3.2 yr (range, 0.5–8.1), and 3.3 yr (range, 0.3–14.0),
respectively; P  0.19]. Moreover, no difference was ob-
served in the percentage with primary infertility (for groups
A, B, and C, 71%, 73%, and 65%, respectively; P  0.70) or
the percentage of patients undergoing IVF/ICSI (for groups
A, B, and C, 22%, 15%, and 18%, respectively; P  0.64). In
the IVF (without ICSI) patients no difference was found in the
sperm quality of the partner [median total motile sperm
count per ejaculate for groups A, B, and C, 45  106 (range,
1.1–420.0), 40.0  106 (range, 0.3–220.0), and 38.8  106
(range, 2.0–180.0), respectively; P  0.94], the incidence of
males with a total motile sperm count below 5.0 106 (by 2
test, P  0.57; data not shown), or the distribution of causes
of infertility (by 2 test, P  0.55; data not shown).
Outcome
Clinical outcome parameters comparing groups A, B, and
C are shown in Table 1 and Fig. 2. A high cancellation rate
because of failure to meet criteria for oocyte retrieval was
observed in group C. Low response leading to cancellation
of the cycle in this group correlated with an increased age and
higher early follicular phase FSH concentrations [median
age, 35 yr (range, 28–39) vs. 33 yr (range, 24–39); P  0.001;
median FSH, 8.0 IU/liter (range, 2.9–29.4) vs. 5.8 IU/liter
(range, 2.1–21.0); P  0.02; for low and normal response
patients, respectively]. In patients with successful stimula-
tion resulting in oocyte retrieval, the total amount of rFSH
used and the duration of FSH stimulation decreased from
group A to group C [Fig. 3; median total amount of rFSH
used for groups A, B, and C, 1650 IU (range, 1050–2250), 1350
IU (900–2100), and 1200 IU (900–1950), respectively; P 
0.001; groups B and C, 18% and 27% decreases, respectively,
vs. group A]. This difference in total amount of rFSH was
more pronounced when the cancelled cycles were included
according to an intention to treat analysis [median total
amount of rFSH used for groups A, B, and C, 1650 IU (range,
1050–2250), 1425 IU (range, 900-2100), and 1050 IU (range,
450-1950), respectively; P  0.001; groups B and C, 14% and
36% decreases, respectively, vs. group A]. Although none of
the participants reaching criteria for oocyte retrieval dem-
onstrated a premature LH surge (LH 10 IU/liter), three
patients (two from group B and one from group C) ovulated
after hCG administration before oocyte retrieval. In one pa-
tient (group C) ET was not carried out due to an imminent
ovarian hyperstimulation syndrome.
The number of follicles on the day of hCG administration,
the number of oocytes retrieved, and the number of embryos
in patients in whom oocytes could be retrieved are given in
Table 1. After oocyte retrieval, the best embryo was more
FIG. 2. Percentage of women undergoing
oocyte retrieval per started IVF cycle, per-
centage of women undergoing ET per oo-
cyte retrieval and per started cycle, preg-
nancies per ET, and pregnancies per
started IVF cycle, comparing a GnRH ag-
onist long protocol (group A) with two
GnRH antagonist protocols with start of
exogenous FSH on cycle d 2 (group B) or
cycle d 5 (group C). Comparisons were
performed using the 2 test.
FIG. 3. Duration of rFSH stimulation (in days) and the total dose of
rFSH used (in international units per cycle) in 104 patients under-
going oocyte retrieval, comparing three different ovarian stimulation
protocols for IVF: a GnRH agonist long protocol (group A) vs. two
GnRH antagonist protocols, starting rFSH on either cycle d 2 (group
B) or cycle d 5 (group C). As a fixed dose of rFSH (150 IU/d) was used,
the total amount of rFSH used was directly related to the length of
stimulation. Boxes indicate 25th and 75th percentiles, with the hor-
izontal line representing the median value. Whiskers span the range
observed. Comparisons were performed using the Kruskal-Wallis H
test.
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frequently scored as 1 in group C (Fig. 4; groups A, B, and
C, 29%, 37%, and 61%, respectively; P  0.008). For the
overall group the quality of the best embryo available for
transfer was directly related to the pregnancy rate (Fig. 4; P
0.009), independent from the use of a GnRH agonist or an-
tagonist (implantation rate when embryo score of best em-
bryo is 1 or 2, 40% for GnRH agonist vs. 39% for GnRH
antagonist; P 1.0). Fewer cycles in group C were cancelled
after oocyte retrieval because of total fertilization failure or
abnormal embryo development (groups A, B, and C, 32%,
29%, and 7%, respectively; P  0.03). For IVF without ICSI,
the occurrence of total fertilization failure was related to
sperm quality [median total motile sperm count, 47.5  106
(range, 2.0–420.0) vs. 17.0  106 (range, 0.3–75.0), respec-
tively; P  0.008]. Abnormal embryo development was not
related to sperm quality (data not shown). The median day
of ET was not different among the three groups (P  0.93;
data not shown). There was no statistically significant dif-
ference in the quality of the best embryo transferred among
the three groups (percentage of embryo score 1 of best em-
bryo for groups A, B, and C, 42%, 52%, and 64%, respectively;
P  0.11).
Figure 5 shows the number of pregnant or nonpregnant
patients per number of oocytes retrieved, comparing groups
A, B, and C. In 6 of 10 pregnant women in group C, 4 or fewer
oocytes were retrieved, whereas this occurred in none of the
pregnant women in group A and in just 1 patient in group
B (P  0.01). With regard to (ongoing) pregnancy rate per
started cycle, no differences were found among the groups
(Table 1 and Fig. 2). The overall pregnancy rates of the 142
study patients were 21%/started cycle, 29%/oocyte retrieval,
and 38%/ET.
Endocrinology
Table 1 shows E2 levels on the day of hCG in patients
reaching oocyte retrieval. Figure 6 shows the serum FSH
concentrations during the follicular phase of the treatment
cycle in all patients reaching criteria for oocyte retrieval,
comparing groups A, B, and C. In groups A and B, FSH
concentrations increased between cycle d 2 and 5 [median
FSH d 2 vs. d 5 for group A, 5.1 IU/liter (range, 2.6–9.9) vs.
7.3 IU/liter (range, 3.5–13.0); P  0.001); for group B, 6.2
IU/liter (range, 2.0–10.9) vs. 6.9 IU/liter (range, 3.8–14.4);
P  0.02] and decreased between cycle d 5 and day of hCG
administration (median FSH d 5 vs. day of hCG, data pre-
sented above and in Table 1; P  0.04 for group A; P  0.02
for group B). However, in group C, FSH concentrations re-
mained constant during the follicular phase [median FSH on
d 2, 5.9 IU/liter (range, 2.1–21.0); on d 5, 5.7 IU/liter (range,
3.2–15.9); P 0.98; day of hCG, 6.8 IU/liter (range, 3.5–12.7);
P  0.08].
Discussion
The concept of extending the FSH window to induce the
development of multiple dominant follicles for IVF by ad-
ministering exogenous FSH from the midfollicular phase
onward combined with the use of GnRH antagonists con-
stitutes a novel strategy for mild ovarian stimulation. As
FIG. 4. Bar diagrams representing the percentage of embryos with a
score of 1 (see Subjects and Methods for definitions) after oocyte
retrieval in 104 patients, comparing a GnRH agonist long protocol
(group A; n  38) with two GnRH antagonist protocols commencing
rFSH on cycle d 2 (group B; n  35) or cycle d 5 (group C; n  31; left
panel) and the pregnancy rate per embryo score of the best embryo
transferred in 79 patients undergoing ET (right panel). Comparisons
were performed using the 2 test.
FIG. 5. Relation between the number of oocytes retrieved and preg-
nancy, comparing a GnRH agonist long protocol (group A; n 38) with
two GnRH antagonist protocols with start of rFSH on cycle d 2 (group
B; n  35) or cycle d 5 (group C; n  31). Bars represent the total
number of patients () and pregnant patients separately (f) per
number of oocytes retrieved. Lines represent the percentage of preg-
nant women, cumulative over the number of oocytes obtained. The
shaded area represents patients in whom four or fewer oocytes were
obtained and for whom the chance of pregnancy is significantly dif-
ferent comparing groups A, B, and C (by 2 test, P  0.01).
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GnRH antagonist action is characterized by an immediate
suppression of pituitary gonadotropin release (5, 24), these
compounds offer the opportunity to commence the IVF treat-
ment cycle in an undisturbed menstrual cycle. This study
shows that the stimulating capacity of endogenous FSH can
be exploited during the early follicular phase for the cyclic
recruitment of a cohort of early antral follicles. Commencing
exogenous FSH during the midfollicular phase results in
multiple dominant follicle development despite a substantial
reduction in the amount of exogenous FSH required.
In the GnRH antagonist d 5 group, significantly more
cancellations due to low response were observed compared
with the GnRH agonist and GnRH antagonist d 2 groups. We
observed a significant difference in age and baseline FSH,
between the cancelled patients and those who met criteria for
oocyte retrieval in the GnRH antagonist d 5 group. This may
indicate that a subgroup of women likely to have a low
response to mild stimulation can be identified before the
onset of the IVF. In contrast to previous reports, this differ-
ence in age and FSH between low and normal response
patients was not found in the GnRH agonist or the GnRH
antagonist d 2 groups. This is probably due to the relatively
low number of patients involved. Compared with previous
studies (17, 25, 26), we observed a relatively high cancellation
rate (16% and 27%) before oocyte retrieval in both the GnRH
agonist and the GnRH antagonist d 2 groups. This may be
explained by differences in patient selection for IVF and
differences in treatment protocols, as we used a fixed dose of
exogenous FSH. In addition, cancellation criteria in minimal
stimulation protocols may need to be revised due to the
observed pregnancies in women with a low oocyte yield.
For those patients in the GnRH antagonist d 5 group who
met criteria for oocyte retrieval, the duration of stimulation
was shorter than in both other groups, resulting in a 27%
reduction in the total amount of exogenous FSH required.
The 14% reduction in the total amount of exogenous FSH
used comparing the GnRH antagonist d 2 vs. the GnRH
agonist group was comparable to differences observed in
previous studies (13–17). A reduction in exogenous FSH may
affect ovarian response, usually assessed by the number of
follicles that have developed and the E2 levels during the late
follicular phase. A reduced ovarian response will result in
fewer oocytes after retrieval and probably a reduction in the
number of resulting embryos. Given the close correlation
between the number of embryos from which to select and the
chance of pregnancy (1), pregnancy rates may suffer from
less profound stimulation protocols. We did observe a ten-
dency toward the development of fewer dominant follicles
(10 mm) in the GnRH antagonist d 5 group. However, as
no difference was found between the development of larger
follicles (15 mm), mainly contributing to the production of
E2 (27), no difference was observed in E2 levels on the day
of hCG administration among the three studied stimulation
protocols. Thus, in those patients achieving multifollicular
growth after extending the FSH window, a normal ovarian
response was seen. The concern that fewer oocytes will be
obtained after milder stimulated cycles resulting in fewer
pregnancies is therefore not supported by our findings. De-
spite a tendency toward the development of fewer dominant
follicles, no difference was seen in the number of oocytes
retrieved.
The median fertilization rate per subject did not differ
among the three groups, and consequently, the median num-
bers of embryos obtained were comparable. However, as
more patients in the GnRH agonist and GnRH antagonist d
2 groups were cancelled because of a total fertilization failure
or abnormal embryo development, patients in the GnRH
antagonist d 5 group presented with a better chance of un-
dergoing ET, compensating for the observed increased can-
cellation rate. Compared with previous studies reporting
transfer rates after oocyte retrieval between 80–95% (25, 26),
68–90% of the patients participating in the current study
underwent ET. This difference may be explained by the rel-
atively small proportion of patients undergoing ICSI (18%)
and differences in patient inclusion, laboratory performance,
and the small number of patients in the current study. When
the criteria for oocyte retrieval were met in the current study,
the chance of subsequently producing good quality embryos
was significantly increased in the GnRH antagonist d 5
group. Milder stimulation may result in selection of good
quality oocytes, which may result in better quality embryos.
Although embryo quality is not the only factor determining
implantation rate, embryo score is predictive of pregnancy
(28). Our study provides further confirmation that high qual-
ity embryos are more likely to implant and result in preg-
nancy. Despite a better chance of retrieving high quality
embryos, the patients in the GnRH antagonist d 5 group
demonstrated a comparable pregnancy rate per ET. It has
been suggested that the use of GnRH antagonists is associ-
ated with reduced implantation rates compared with con-
ventional protocols (5). This could not be confirmed in the
current study, which may be related to the flexible GnRH
antagonist protocol applied.
Overall, the pregnancy rate per started IVF cycle was com-
parable in the three groups, with a pregnancy rate of 21%/
started cycle for all patients together. Despite our relatively
high cancellation rates during the stimulation phase or after
FIG. 6. FSH serum concentrations (mean  SEM) in the follicular
phase of an IVF stimulation cycle in 104 patients undergoing oocyte
retrieval, comparing a GnRH agonist long protocol (group A) with two
GnRH antagonist protocols, with start of rFSH on cycle d 2 (group B)
or cycle d 5 (group C). The time scale on the x-axis is divided into cycle
days (group A: day of start rFSH  cycle d 1; groups B and C: day of
onset of menses  cycle d 1) and day of administration of hCG. FSH
on cycle d 5 is statistically different comparing groups A, B, and C.
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oocyte retrieval, these results are comparable to the percent-
ages reported elsewhere. European studies report pregnancy
rates per started cycle varying between 16–26%, with a mean
of 21% (25). American studies tend to report higher percent-
ages of pregnancies per started cycle (delivery rate per
started cycle of 25%), but at the cost of extended, complex,
and expensive stimulation protocols and increased chances
for higher order multiple pregnancies due to the transfer of
more than two embryos (26). Many studies from individual
centers only mention pregnancy rates per oocyte retrieval or
per ET, which are in the same range as the overall pregnancy
rates observed in the current study (29%/oocyte retrieval
and 38%/ET).
A low response during ovarian stimulation is currently
believed to represent ovarian aging and poor oocyte quality
(29–31). However, a low number of oocytes after mild stim-
ulation may constitute a normal response, resulting in high
quality oocytes and embryos. In our study the response of
four or fewer oocytes after profound ovarian stimulation
(group GnRH agonist or GnRH antagonist d 2) observed in
19% of the patients was indeed associated with impaired
pregnancy outcome (only 7% of these patients conceived).
However, after mild stimulation, the presence of four or
fewer oocytes (observed in 29% of the patients) was associ-
ated with a good chance of pregnancy (67% of these patients
conceived). This indicates that a low number of oocytes ob-
tained after minimal stimulation may represent a selection of
oocytes more likely to result in pregnancy. The low total dose
of exogenous FSH may only stimulate the most mature fol-
licles to ongoing growth, allowing a degree of selection of
oocytes to occur.
The advantages of mild ovarian hyperstimulation for IVF
are being increasingly recognized (2, 3, 32). The reduction in
the duration of ovarian stimulation (fewer injections) com-
bined with fewer side-effects (14) diminish patient discom-
fort and reduce costs. Milder stimulation may require less
monitoring, because short-term complications and long-term
risks are expected to be reduced, although this remains to be
established in a larger series of patients. Despite these ad-
vantages, a lower ovarian response after milder stimulation
resulting in an increased cancellation rate before oocyte re-
trieval has been put forward as an argument against the use
of these protocols and restrained its introduction into clinical
practice. However, despite the higher rate of cancellations in
the GnRH antagonist d 5 group, the overall outcome did not
differ among the three groups. This raises the question of
whether this higher incidence of low ovarian response, and
thus higher cancellation rate before oocyte retrieval, is, in
fact, detrimental for overall IVF outcome. The cancelled pa-
tients in the GnRH antagonist d 5 group may represent those
with a poor chance of a high quality ET, with impaired
chances to conceive in IVF. As cancellation after mild stim-
ulation can partly be predicted by age and early follicular
FSH concentrations (two markers of ovarian reserve), low
response after mild stimulation may allow patient selection
before oocyte retrieval, avoiding subsequent procedures that
are unlikely to lead to pregnancy. Moreover, cancellation of
a cycle after a short stimulation should be viewed differently
from cancellation after a prolonged stimulation period. This
earlier selection of poor prognosis patients may improve
overall health economics of IVF for the majority of patients.
The finding that a low number of oocytes obtained after
minimal stimulation is associated with good pregnancy
chances indicates that a large number of oocytes is not re-
quired for a successful IVF program. Although the criteria for
oocyte retrieval did not differ among the protocols in this
study, in retrospect these findings suggest the need for an
adjustment of minimal criteria for oocyte retrieval after
milder stimulation. A physiological reduction in the number
of oocytes generated after mild ovarian stimulation distinctly
differs from a pathological reduction associated with ovarian
aging. The clinical introduction of GnRH antagonists allows
a more physiological approach to ovarian stimulation. More-
over, the trend toward single ET, avoiding multiple preg-
nancies (33, 34), reduces further the need for high numbers
of oocytes and embryos. The present study demonstrates the
clinical applicability of the concept of extending the FSH
window for ovarian stimulation in IVF. However, the full
clinical potential of the described mild stimulation protocol
requires confirmation in larger multicenter studies.
Acknowledgments
Dr. D. de Jong is kindly acknowledged for his assistance with patient
monitoring and serum collection.
Received May 22, 2002. Accepted October 10, 2002.
Address all correspondence and requests for reprints to: Prof.
B. C. J. M. Fauser, M.D., Ph.D., Division of Reproductive Medicine,
Department of Obstetrics and Gynecology, Erasmus Medical Center, Dr.
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail:
fauser@gyna.azr.nl.
This work was supported by the Stichting Voortplantings-
geneeskunde Rotterdam and an unrestricted research grant from ASTA
Medica B.V. (Amsterdam, The Netherlands).
References
1. Templeton A, Morris JK 1998 Reducing the risk of multiple births by transfer
of two embryos after in vitro fertilization. N Engl J Med 339:573–577
2. Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WF, Baird DT, Bouchard
P 1999 Minimal ovarian stimulation for IVF: appraisal of potential benefits and
drawbacks. Hum Reprod 14:2681–2686
3. Edwards RG, Lobo R, Bouchard P 1996 Time to revolutionize ovarian stim-
ulation. Hum Reprod 11:917–919
4. Fauser BC, van Heusden AM 1997 Manipulation of human ovarian function:
physiological concepts and clinical consequences. Endocr Rev 18:71–106
5. Al Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a
Cochrane review. Hum Reprod 17:874–885
6. Macklon NS, Fauser BC 2000 Regulation of follicle development and novel
approaches to ovarian stimulation for IVF. Hum Reprod Update 6:307–312
7. Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BC 1990 Growth
patterns of nondominant ovarian follicles during the normal menstrual cycle.
Fertil Steril 54:638–642
8. van Santbrink EJ, Hop WC, van Dessel TJ, de Jong FH, Fauser BC 1995
Decremental follicle-stimulating hormone and dominant follicle development
during the normal menstrual cycle. Fertil Steril 64:37–43
9. Baird DT 1987 A model for follicular selection and ovulation: lessons from
superovulation. J Steroid Biochem 27:15–23
10. Fauser BC, Donderwinkel P, Schoot DC 1993 The step-down principle in
gonadotrophin treatment and the role of GnRH analogues. Bailliere Clin Ob-
stet Gynaecol 7:309–330
11. Schipper I, Hop WC, Fauser BC 1998 The follicle-stimulating hormone (FSH)
threshold/window concept examined by different interventions with exoge-
nous FSH during the follicular phase of the normal menstrual cycle: duration,
rather than magnitude, of FSH increase affects follicle development. J Clin
Endocrinol Metab 83:1292–1298
12. Hohmann FP, Laven JS, de Jong FH, Eijkemans MJ, Fauser BC 2001 Low-dose
exogenous FSH initiated during the early, mid or late follicular phase can
induce multiple dominant follicle development. Hum Reprod 16:846–854
13. Albano C, Felberbaum RE, Smitz J, Riethmu¨ller-Winzen H, Engel J, Diedrich
172 J Clin Endocrinol Metab, January 2003, 88(1):166–173 Hohmann et al. • Minimal Ovarian Stimulation for IVF
 on November 14, 2006 jcem.endojournals.orgDownloaded from 
K, Devroey P, on behalf of the European Cetrorelix Study Group 2000
Ovarian stimulation with HMG: results of a prospective randomized phase III
European study comparing the luteinizing hormone-releasing hormone
(LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod
15:526–531.
14. The European Orgalutran Study Group, Borm G, Mannaerts B 2000 Treat-
ment with the gonadotrophin-releasing hormone antagonist ganirelix in
women undergoing ovarian stimulation with recombinant follicle stimulating
hormone is effective, safe and convenient: results of a controlled, randomized,
multicentre trial. Hum Reprod 15:1490–1498
15. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau
L, Nicolett B, Zorn JR, Bouchard P, Frydman R 2000 Prospective, randomized,
controlled study of in vitro fertilization-embryo transfer with a single dose of
a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or
a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73:314–320
16. The North American Ganirelix Study Group: Fluker M, Grifo J, Leader A,
Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT,
Schoolcraft W, Shapiro DB 2001 Efficacy and safety of ganirelix acetate versus
leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fertil Steril 75:38–45
17. The European and Middle East Orgalutran Study Group 2001 Comparable
clinical outcome using the GnRH antagonist ganirelix or a long protocol of the
GnRH agonist triptorelin for the prevention of premature LH surges in women
undergoing ovarian stimulation. Hum Reprod 16:644–651.
18. de Jong D, Macklon NS, Fauser BC 2000 A pilot study involving minimal
ovarian stimulation for in vitro fertilization: extending the “follicle-stimulating
hormone window” combined with the gonadotropin-releasing hormone an-
tagonist cetrorelix. Fertil Steril 73:1051–1054
19. Huisman GJ, Fauser BC, Eijkemans MJ, Pieters MH 2000 Implantation rates
after in vitro fertilization and transfer of a maximum of two embryos that have
undergone three to five days of culture. Fertil Steril 73:117–122
20. Veeck LL 1998 An atlas of human gametes and conceptuses. New York:
Parthenon; 40–45
21. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD 1991
Serum bioactive and immunoreactive luteinizing hormone and follicle-stim-
ulating hormone levels in women with cycle abnormalities, with or without
polycystic ovarian disease. J Clin Endocrinol Metab 73:811–817
22. Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP, Mc-
Neilly AS 1996 Measurement of dimeric inhibin B throughout the human
menstrual cycle. J Clin Endocrinol Metab 81:1401–1405
23. Beckers NG, Laven JS, Eijkemans MJ, Fauser BC 2000 Follicular and luteal
phase characteristics following early cessation of gonadotrophin-releasing hor-
mone agonist during ovarian stimulation for in-vitro fertilization. Hum Re-
prod 15:43–49
24. Christin-Maitre S, Olivennes F, Dubourdieu S, Chabbert-Buffet N, Char-
bonnel B, Frydman R, Bouchard P 2000 Effect of gonadotrophin-releasing
hormone (GnRH) antagonist during the LH surge in normal women and
during controlled ovarian hyperstimulation. Clin Endocrinol (Oxf) 52:721–726
25. Nygren KG, Andersen AN 2001 Assisted reproductive technology in Europe,
1998. Results generated from European registers by ESHRE. European Society
of Human Reproduction and Embryology. Hum Reprod 16:2459–2471
26. ASRM/SART registry 2002 Assisted reproductive technology in the United
States: 1998 results generated from the American Society for Reproductive
Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril
77:18–31
27. van Dessel HJ, Schipper I, Pache TD, van Geldorp H, de Jong FH, Fauser BC
1996 Normal human follicle development: an evaluation of correlations with
oestradiol, androstenedione and progesterone levels in individual follicles.
Clin Endocrinol (Oxf) 44:191–198
28. Hunault CC, Eijkemans MJ, Pieters MH, te Velde ER, Habbema JD, Fauser
BC, Macklon NS 2002 A prediction model for selecting patients undergoing
in vitro fertilization for elective single embryo transfer. Fertil Steril 77:725–732
29. Nikolaou D, Lavery S, Turner C, Margara R, Trew G 2002 Is there a link
between an extremely poor response to ovarian hyperstimulation and early
ovarian failure? Hum Reprod 17:1106–1111
30. de Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, Klip H, van Leeuwen
FE 2002 A low number of retrieved oocytes at in vitro fertilization treatment
is predictive of early menopause. Fertil Steril 77:978–985
31. Beckers NG, Macklon NS, Eijkemans MJ, Fauser BC 2002 Women with
regular menstrual cycles and a poor response to ovarian hyperstimulation for
in vitro fertilization exhibit follicular phase characteristics suggestive of ovar-
ian aging. Fertil Steril 78:291–297
32. Edwards RG, Lobo RA, Bouchard P 1997 Why delay the obvious need for
milder forms of ovarian stimulation? Hum Reprod 12:399–401
33. Gerris J, de Neubourg D, Mangelschots K, van Royen E, van de Meerssche
M, Valkenburg M 1999 Prevention of twin pregnancy after in-vitro fertiliza-
tion or intracytoplasmic sperm injection based on strict embryo criteria: a
prospective randomized clinical trial. Hum Reprod 14:2581–2587
34. Martikainen H, Tiitinen A, Tomas C, Tapanainen J, Orava M, Tuomivaara
L, Vilska S, Hyden-Granskog C, Hovatta O 2001 One versus two embryo
transfer after IVF and ICSI: a randomized study. Hum Reprod 16:1900–1903
Hohmann et al. • Minimal Ovarian Stimulation for IVF J Clin Endocrinol Metab, January 2003, 88(1):166–173 173
 on November 14, 2006 jcem.endojournals.orgDownloaded from 
